Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases.
Advancing transformative medicines for neurological diseases.
![temp_pipeline_crop](https://www.voyagertherapeutics.com/wp-content/uploads/2023/10/temp_pipeline_crop.png)
Our pipeline includes genetic medicines for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system.
Revolutionizing delivery across the blood-brain barrier.
Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which has generated novel capsids that demonstrate exceptional delivery across the blood-brain barrier following intravenous dosing in preclinical studies.
![vcap195-ribbon-surface_sm_web](https://www.voyagertherapeutics.com/wp-content/uploads/2023/12/vcap195-ribbon-surface_sm_web.jpg)
Our people are our most valuable resource.
We are looking for dedicated professionals who share our passion for advancing transformative neurogenetic medicines.